MedTrace Logo

Freiburg ZNS-NHL Study

NCT00647049 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2009-11-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether combined chemotherapy \[rituximab plus high dosage methotrexate (max. 2 cycles) followed by arabinoside/thiotepa (max. 2 cycles) followed by high dosage carmustin/thiotepa\] followed by peripheral blood stem cell transplantation is effective in the treatment of cerebral Non Hodgkin lymphoma \[PCNSL\].

Conditions

  • Primary Non Hodgkin Lymphoma of the Central Nervous System

Interventions

DRUG

methotrexate

8000mg/m2 i.v., max. 2 cycles

DRUG

Rituximab

375mg/m2, max. 8 times

DRUG

Cytarabine

3000mg/m2 die i.v., 2 days (max. 2 cycles)

DRUG

Thiotepa

40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days

DRUG

Carmustin

400mg/m2 i.v. for 1 day

Sponsors & Collaborators

  • University Hospital Tuebingen

    collaborator OTHER

  • University Hospital Freiburg

    lead OTHER

Principal Investigators

  • Jürgen Finke, Prof. Dr. · University Medical Center Freiburg, Dept. of Internal Medicine I - Hematology and Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2013-05-31
Completion
2013-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00647049 on ClinicalTrials.gov